UPLOAD Filing
Pasithea Therapeutics Corp.
Date: Sept. 2, 2025 · CIK: 0001841330 · Accession: 0000000000-25-009455
AI Filing Summary & Sentiment
Reasoning
Letter
September 2, 2025 Tiago Reis Marques Chief Executive Officer Pasithea Therapeutics Corp. 1111 Lincoln Road, Suite 500 Miami Beach, FL 33139 Re:Pasithea Therapeutics Corp. Draft Registration Statement on Form S-1 Submitted August 28, 2025 CIK No. 0001841330 Dear Tiago Reis Marques: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:James B. O'Grady
Show Raw Text
September 2, 2025
Tiago Reis Marques
Chief Executive Officer
Pasithea Therapeutics Corp.
1111 Lincoln Road, Suite 500
Miami Beach, FL 33139
Re:Pasithea Therapeutics Corp.
Draft Registration Statement on Form S-1
Submitted August 28, 2025
CIK No. 0001841330
Dear Tiago Reis Marques:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft
submission on EDGAR at least two business days prior to the requested effective date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:James B. O'Grady